CTI
BioPharma Corp. (Nasdaq: CTIC) reported positive data from a Phase 3
registration-directed trial of pacritinib to treat myelofibrosis lifting the stock price 39 cents to $2.33.
Positive data from CTI BioPharma
June 01, 2015 at 13:54 PM EDT